<DOC>
	<DOCNO>NCT01427972</DOCNO>
	<brief_summary>The purpose trial investigate safety efficacy LY2623091 males female chronic kidney disease .</brief_summary>
	<brief_title>A Study LY2623091 Male Females With Chronic Kidney Disease</brief_title>
	<detailed_description>This trial consist 4 treatment arm : 3 LY2623091 dose level eplerenone . Each patient participate 2 treatment period , minimum wash-out period 28 day dose 2 treatment period . Dosing day number 1-21 2 treatment period . Patients receive different treatment period 1 2 . Patients house inpatient day control diet administration oral potassium challenge least 24 hour completion ( Days -3 1 ; Days 19 22 , treatment period ) . Otherwise study do outpatient basis , patient return clinic evaluation treatment period ( Days 3 4 , 7 , 14 ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Men woman nonchildbearing potential determined medical history physical examination 1 . Male patient : Nonvasectomized male patient must agree use 2 medically accept method contraception sexual partner study 90 day follow final dosing . Medically accept effective form contraception may include condom contraceptive foam partner use diaphragms contraceptive jelly cervical cap contraceptive jelly 2 . Female patient : Female patient must nonchildbearing potential due surgical sterilization ( hysterectomy , bilateral oophorectomy tubal ligation ) menopause . Postmenopausal woman minimum 12 month without menstrual period . Perimenopausal woman 6 month without menstrual period , follicle stimulate hormone level 23.0116.3 international unit/liter ( IU/L ) age 45 65 year , inclusive , also eligible Have diagnose Chronic Kidney Disease ( CKD ) ( include diabetic kidney disease chronic glomerulonephritis ) Have estimate glomerular filtration rate ( eGFR ) 30 70 milliliter/minute/1.73 square meter ( ml/min/1.73m^2 ) Have take Angiotensin convert enzyme ( ACE ) inhibitor and/or Angiotensin II receptor blocker ( ARB ) , least 3 month , stable dose great equal ( ≥ ) 2 month prior randomization , agree continue take throughout duration study Patients must meet following renal function criterion prior qualify randomization : 1 . Have Screening first morning urine Protein/creatinine ratio ( PCR ) ≥400 milligram/gram ( mg/g ) 2 . Have stable renal function , opinion Investigator Stable use blood pressure ( BP ) medication acceptable cuff BP , define follow criterion : 1 . While receive stable dose ACE inhibitor and/or ARB 2 . While receive stable dos applicable BP medication ( include diuretic therapy ) ≥3 week prior screen 3 . Have seat cuff systolic BP le equal ( ≤ ) 160 millimeter mercury ( mm Hg ) diastolic BP ≤100 mm Hg Have serum potassium ( K+ ) ≤ 5.0 milliequivalents/liter ( mEq/L ) Screening , 1 hospitalization due hyperkalemia within 1 year Are reliable willing make available duration study willing follow specific study procedure Have venous access sufficient allow blood sample Have lab value safety parameter , opinion investigator , acceptable participation study Patients currently enrol , discontinue within last 30 day investigational drug , clinical trial involve investigational drug device offlabel use approve drug ( study drug use study ) , concurrently enrol type medical research judge scientifically medically compatible study . Patients may enrol study dose day 31 great follow last day previous investigational drug administration Have previously complete withdrawn study study investigate LY2623091 Patients take diuretic drug receive stable dose 3 week prior screening/qualification visit end treatment Patients receive renin inhibitor , Mineralocorticoid receptor ( MR antagonist ) must washout period least 1 month prior randomization Patients dialysis renal transplantation anticipate physician within 6 month Screening Patients history acute kidney injury within 3 month Screening Patients expect require systemic immunosuppression therapy within 30 day Screening ( except inhalant steroid ) Use oral parenteral corticosteroid within 30 day Screening Patients diagnosis Class three ( III ) four ( IV ) congestive heart failure ( defined New York Heart Association ) Patients evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody ; patient history cirrhosis hepatitis C positive hepatitis C antibody Screening ; patient know hepatitis B surface antigenpositive positive hepatitis B surface antigen Screening Patients unwilling unable comply use data collection device directly record data patient Use metabolizing enzyme ( CYP3A4 ) inhibitor inducer , potassium spar diuretic drug ( diuretic drug allow , potassium supplement systemic glucocorticoid within 7 day study enrollment . Intermittent use nonsteroidal antiinflammatory drug ( NSAIDs ) permit , except within 24 hour critical urine sodium/potassium measure inpatient period , time NSAID use limit chronic use ( stable ≥ 1 month prior enrollment ) . Prostaglandin inhibitor use inpatient period study , exception chronic NSAID use Have donate blood 500 milliliter ( mL ) within last 60 day screen Have average weekly alcohol intake exceed 21 unit per week patient unwilling stop alcohol intake within 48 hour entry study duration study ( 1 unit equal 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Evidence regular use drug abuse Consumption natural licorice and/or natural licoricecontaining product and/or regular daily consumption grapefruit and/or grapefruit juice within 7 day first dose and/or anticipate consumption study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>